The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-Blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID

Individuals with long COVID lack evidence-based treatments and have difficulty participating in traditional site-based trials. Our digital, decentralized trial investigates the efficacy and safety of nirmatrelvir/ritonavir, targeting viral persistence as a potential cause of long COVID. The PAX LC t...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The American journal of medicine 2024-05
Hauptverfasser:	Krumholz, Harlan M., Sawano, Mitsuaki, Bhattacharjee, Bornali, Caraballo, César, Khera, Rohan, Li, Shu-Xia, Herrin, Jeph, Coppi, Andreas, Holub, Julie, Henriquez, Yashira, Johnson, Maria A., Goddard, Theresa B., Rocco, Erica, Hummel, Amy C., AL Mouslmani, Mohammad, Putrino, David F., Carr, Kevin D., Carvajal-Gonzalez, Santos, Charnas, Lawrence, De Jesus, Magdia, Ziegler, Frank W., Iwasaki, Akiko
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical trial Decentralized Long COVID Nirmatrelvir/ritonavir PROMIS-29
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!